Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
2016
Bennett, J., et al. (2016).
Lancet 388(10045): 661-672
2016
Bennett, J., et al. (2016).
Lancet 388(10045): 661-672